Abstract:Background: Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease characterized by painful nodules, drainage and scarring in skin folds. Injectable adalimumab is the only drug approved by the US Food and Drug Administration for the treatment of HS. Although systemic Janus kinase (JAK) inhibitors show promise, serious side-effects have been reported. There are no highly effective topical treatments for HS; furthermore, the contribution of epidermal keratinocytes to the intense inflammation has largely been unexplored. Objectives: We investigated the role of keratinocytes and epidermal immune cells in HS inflammation at all Hurley stages of disease severity. We aimed to determine whether ruxolitinib can mitigate inflammation from keratinocytes and to develop a better understanding of how topical therapeutics might benefit patients with HS. Methods: We used skin samples from 87 patients with HS (Hurley stages I-III) and 39 healthy controls to compare keratinocyte- and immune cell-driven epidermal inflammation, in addition to the response of lesional HS keratinocytes to treatment with interferon (IFN)-γ and ruxolitinib. We used haematoxylin and eosin staining, immunohistochemistry, immunoblotting and quantitative reverse-transcription polymerase chain reaction assessments in whole skin, isolated epidermis, and cultured keratinocytes from healthy controls and both nonlesional and lesional HS skin to identify and define epidermal and keratinocyte-mediated inflammation in HS and how this may be targeted by therapeutics. Results: HS lesional keratinocytes autonomously secreted high levels of chemokines, such as CCL2, CCL3 and CXCL3, which recruited neutrophils, CD8 T cells, and natural killer cells to the epidermis. Keratinocytes were the dominant source of tumour necrosis factor-α and interleukin (IL)-6 in HS lesions with little to no contribution from underlying dermal immune cells. In the presence of IFN-γ, which is dependent on immune cell infiltrate in vivo, keratinocytes expressed increased levels of additional cytokines including IL-1β, IL-12, IL-23 and IL-36γ. The JAK inhibitor ruxolitinib mitigated the expression of inflammatory cytokines and chemokines in HS lesional keratinocytes, thus providing a rationale for future study as a topical treatment for HS. Conclusions: This study demonstrates that keratinocytes actively recruit immune cells to HS epidermis and interactions between these cells drive a broad inflammatory profile in HS epidermis. Targeting epidermal inflammation in HS with novel topical formulations may be highly efficacious with reduced systemic side-effects.

Unraveling the Role of Sex Hormones on Keratinocyte Functions in Human Inflammatory Skin Diseases

Skin Immunity and Its Dysregulation in Atopic Dermatitis, Hidradenitis Suppurativa and Vitiligo.

Endocrinology of the skin: intradermal neuroimmune network, a new frontier

Sexual hormones in human skin

Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies

Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis

Steroidogenesis in the skin: implications for local immune functions

Crosstalk between keratinocytes and immune cells in inflammatory skin diseases

Immunopathology and Immunotherapy of Inflammatory Skin Diseases

Tumor Necrosis Factor-Alpha: Ally and Enemy in Protean Cutaneous Sceneries

Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

Sex Hormones and Acne: State of the Art

The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis

Skin immunity and its dysregulation in psoriasis.

Potential role of the skin microbiota in Inflammatory skin diseases

Immunomodulatory Plant Natural Products as Therapeutics against Inflammatory Skin Diseases

Epigenetic‐modifying therapies: An emerging avenue for the treatment of inflammatory skin diseases

The role of short-chain fatty acids in inflammatory skin diseases

Sex hormones and acne

Skin Immunity and Its Dysregulation in Psoriasis